Hereditary angioedema - Consequences of a new treatment paradigm in Denmark

Acta Dermato-Venereologica

Volumn 94, Issue 4, 2014, Pages 436-441

  Bygum, Anette ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Burden of illness; Hereditary angioedema; Home therapy; Hospitalisation; Quality of life

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; GLUCOCORTICOID; ICATIBANT; STANOZOLOL; TRANEXAMIC ACID; BRADYKININ; DERMATOLOGICAL AGENT;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; DENMARK; FEMALE; HOME CARE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; ANALOGS AND DERIVATIVES; ANGIOEDEMAS, HEREDITARY; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG ADMINISTRATION; HOSPITALIZATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MOTOR ACTIVITY; PROSPECTIVE STUDY; PSYCHOLOGY; QUALITY OF LIFE; REGISTER; TIME; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; COST OF ILLNESS; DANAZOL; DENMARK; DERMATOLOGIC AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGISTRIES; TIME FACTORS; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 84902816742     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1743     Document Type: Article

References (33)

1. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009; 161: 1153-1158.
2. Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114: S51-131.
3. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
4. Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy 2011; 66: 76-84.
5. López-Lera A, Garrido S, Roche O, López-Trascasa M. SERPING1 mutations in 59 families with hereditary angioedema. Mol Immunol 2011; 49: 18-27.
6. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19: 147-151.
7. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31: 407-414.
8. Jaiganesh T, Hughan C, Webster A, Bethune C. Hereditary angioedema: a survey of UK emergency departments and recommendations for management. Eur J Emerg Med 2012; 19: 271-274.
9. http://www.ouh.dk/wm362032.
10. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
11. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al; HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
12. Bygum A, Zachariae H, Dyerberg J, Kragballe K. Hereditary angioedema. Ugeskr Læger 2004; 166: 362-366 (in Danish).
13. Bygum A, Bork K. Hereditary angioedema. Educational review. Forum for Nord Derm Ven 2006; 11: 47-50.
14. Björkander J, Bygum A, Nielsen EW. Hereditary angioedema. Läkartidningen 2012; 109: 99-103 (in Swedish).
15. Rye Rasmussen EH, Bindslev-Jensen C, Bygum A. Angioedema - assessment and treatment. Tidsskr Nor Laegeforen 2012; 132: 2391-2395.
16. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-531.
17. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
18. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-808.
19. Levy RL, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 523-529.
20. Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107: 529-537.
21. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-522.
22. Åbom AL, Palarasah Y, Bygum A. More new treatment possibilities for hereditary angioedema. Ugeskr Læger 2012; 174: 1894-1898 (in Danish).
23. http://www.R-project.org
24. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-274.
25. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011; 66: 192-196.
26. Craig T, Pürsün EA, Bork K, Bowen T, Boysen H, Farkas H, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5: 182-199.
27. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100: 153-161.
28. Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 2009; 122: 780-783.
29. Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011; 154: 81-88.
30. Huang S-W. Results of an on-line survey of patients with hereditary angioedema. Allergy Asthma Proc 2004; 25: 127-131.
31. Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol 2010; 6: 21.
32. Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147: 11-17.
33. Levi M, Choi G, Picabet C, Hack CE. Self administration of C1 inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-908.